Category Archives: pricing

Spending Rises on Prescription Drugs, Despite Overall Slowdown in Healthcare Outlays

More new medicines came to market in 2013, and fewer blockbuster drugs lost patent protection, trends that federal analysts say led to more rapid growth in outlays for prescription drugs in 2013. Retail prescription drug spending rose 2.5% to reach $271 billion a year ago, much faster than the low growth rate of 0.5% in […]
Also posted in drug spending, healthcare, IP | Tagged , , | 1 Comment

How Gilead “Blew Out the Lights” With Sovaldi

While flipping through my emails recently, I froze before an image that appeared on my screen. An old Rx colleague had sent me a graph, mapping out the 2014 U.S. sales achieved by Gilead’s Hep C drug, Sovaldi. It was stunning. Take a look:
Also posted in Marketing, Strategy | Tagged , , | 2 Comments

Germany Post AMNOG

While emerging markets continue to represent a new channel of demand for pharmaceutical products, manufacturers have quickly realized that significant attention must still be given to more established markets, such as Germany. It’s no longer sufficient to expect that regulatory data from prospective randomized clinical studies alone will be enough to convince payers to provide […]
Also posted in Europe, Guest Blog | Tagged , , , , | Leave a comment

Investment Pros Remain Bullish on Orphans

 An illustrious panel of investment professionals spoke optimistically on the orphan disease space in spite of concerns surrounding escalating drug prices in specialty pharmaceuticals. The group consisting of executives from investment banks, hedge funds, venture capital firms and biopharma companies spoke to the National Organization for Rare Disease (NORD) at its s Rare Diseases and […]
Also posted in Orphan Drugs | Tagged , , | Leave a comment
  • Categories

  • Meta